Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Industry Confident About Device Tax Repeal, But It's Still Vehicle-Shopping

Executive Summary

AdvaMed CEO Scott Whitaker says he is as confident as ever that permanent device tax repeal will happen this year. The only question is, he suggests, what legislative vehicle will bring it over the finish line. User-fee and children's health-insurance reauthorizations are options, along with tax reform, he says.

You may also be interested in...

Capitol Hill Update: Congress Gets Reprieve On User Fee Passage, While AdvaMed Weighs Device Tax Options

Commissioner Gottlieb says the agency won't issue layoff notices "unless and until Sept. 30 passes without reauthorization" of US FDA user fee programs. Meanwhile, could the user fee bill be a vehicle for device tax repeal?

Industry Execs Lobby US Secretaries Ross, Price On Medtech Issues

A group of top medical device executives led by AdvaMed CEO Scott Whitaker met the US commerce and health secretaries to discuss key industry issues, including device tax repeal, FDA user-fee reauthorization, trade policies and reimbursement.

Device Tax Repeal Passes House With GOP Health-Care Bill

The American Health Care Act, which passed the House by a narrow margin May 4, remains unpopular in the country and in the Senate, but the positive vote keeps it alive as a potential vehicle for permanent repeal of the device excise tax.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts